This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Sep 2019

Arcinova Appoints New CEO To Continue Rapid Expansion

Roger Kilburn

Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Northumberland, England, is pleased to announce the appointment of Roger Kilburn as its new CEO. The current CEO, Ian Shott, will now move to the position of Executive Chairman.

The appointment of Roger Kilburn further strengthens the executive management team at Arcinova as it continues its successful growth and further matures as a business. The company now has over 150 employees and has served over 180 customers since its inception.

Roger Kilburn brings a wealth of experience to the role with more than 25 years’ of international experience in the pharmaceutical and chemical industries. He has worked in a variety of roles within general management, marketing, sales, manufacturing, projects and engineering.

He has a solid track record and passion for developing high growth organisations and strong performance teams, along with achieving rapid project success. Prior to his most recent position as CEO of IBioIC, Roger worked for Johnson Matthey and ICI in business leader positions. He also holds a 1st class Honours degree in Chemical Engineering from the University of Glamorgan.

Ian Shott, Executive Chairman, commented, “I am delighted that Roger is taking over this crucial role and certain that his experience leading both Macfarlan Smith in Edinburgh and JM Pharma Services in Boston, Massachusetts gives him an excellent foundation to steer Arcinova through its critical scale up phase, creating a strong and sustainable medium sized enterprise.”

Roger Kilburn said, “It is an immense privilege to lead Arcinova during this next growth stage. I look forward to working with our exceptionally skilled team to enable more clients to benefit from an accelerated path to drug development.”

Mentioned Companies
View company profile